<DOC>
	<DOCNO>NCT00169585</DOCNO>
	<brief_summary>Multicentric , national , prospective , parallel group , control . The Subjects every center randomize assigned pharmacologic arm one biochemical monitoring</brief_summary>
	<brief_title>Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen ( PSA )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Only subject meet follow criterion eligible participate study : Male patient Age ≥ 45 year Suspected presence prostate inflammatory focus , define accord follow criterion : PSA ≥ 2.6 ng/mL age ≥ 50 &lt; 60 year ( ≥ 45 year patient know family predisposition carcinoma prostate ) , PSA ≥ 4.1 ng/mL age ≥ 60 &lt; 75 year , normal digitorectal examination ( DRE ) ( see section 5.2 ) , normal urine test dipstick and/or microscopy carry within 5 day baseline visit Patients willing able provide write informed consent comply study procedure . Patients LUTS/BPH watchful wait already treatment alphablockers 5ARI ( 5alpha reductase inhibitor ) least 6 month also consider eligible participate study . Patients meet follow criterion eligible participate study : Diagnosis NIH class IIII prostatitis clinical evidence active acute urinary infection and/or know suspect active bacterial infection site ; Diagnosis prostate carcinoma ( PIN ASAPS ) prior radical prostatectomy radiotherapy treatment prostate cancer ; PSA &gt; 20 ng/mL ; PSA value ( include high value ) stable time ; Start pharmacological therapy 5ARI subject LUTS/BPH ; Permanent catheter ; Prior treatment ( within 4 week ) levofloxacin genitalurinary infection ; Known suspect allergy levofloxacin , include excipients contain pharmacological preparation and/or confirm tendency photosensitivity reaction fluoroquinolone therapy ; Concomitant treatment drug allow study Reluctance undergo prostate biopsy and/or risk noncompliance ; History current evidence alcohol drug abuse last 12 month ; History condition , opinion investigator , may confound study result create additional risk patient . Participation study investigational market drug within 30 day baseline visit study .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>diagnostic-therapeutic pathway</keyword>
	<keyword>PSA</keyword>
	<keyword>DRE</keyword>
	<keyword>Levofloxacin</keyword>
</DOC>